Table 2.
Signature | Reference | Type | Developed for |
---|---|---|---|
1. PAM50 – AIMS | 23 | GEP | All breast cancer |
2. PAM50* | 38 | GEP | All breast cancer |
3. IC10 | 11, 12 | GEP | All breast cancer |
4. CIT | 27 | GEP | All breast cancer |
5. TNBCtype | 28, 46 | GEP | TNBC |
6. HDPP | 43 | GEP | HER2+ breast cancer |
7. SDPP | 42 | GEP | All breast cancer |
8. SCMOD2 | 34 | GEP | All breast cancer |
9. GGI | 39 | RP | All breast cancer |
10. Gene70 | 47 | RP | All breast cancer |
11. Oncotype DX | 7 | RP | ER+ breast cancer |
12. Gene76 | 48 | RP | LN-negative breast cancer |
13. Endopredict | 49 | RP | ER+/HER2− breast cancer |
14. Genius | 37 | RP | All breast cancer |
15. ROR-S* | 38 | RP | All breast cancer |
16. ROR-P* | 38 | RP | All breast cancer |
17. ROR-T* | 38 | RP | All breast cancer |
18. ROR-PT* | 38 | RP | All breast cancer |
19. ROR-Tot* | 8 | RP | All breast cancer |
*Implementation was performed by using a reference set similar in composition to Parker et al.38 for gene centering.
GEP: Gene expression phenotype signature.
RP: Risk prediction signature.